Exelixis had its Relative Strength (RS) Rating upgraded from 70 to 74 Tuesday -- a welcome improvement, but still shy of the 80 or higher score you prefer to see.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
This unique rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the best stocks tend to have an RS Rating of above 80 in the early stages of their moves. See if Exelixis can continue to rebound and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Exelixis broke out earlier, but has fallen back below the prior 20.56 entry from a flat base. It has not fallen over 7%, so the base is still in play, and one to keep on your watchlist.
Earnings growth increased in the company's latest report from -38% to 11%, but revenue fell from 15% to 12%.
The company earns the No. 38 rank among its peers in the Medical-Biomed/Biotech industry group. Arcturus Therapeutics and Kiniksa Pharmaceuticals are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
